argenx Reports Third Quarter 2026 Financial Results and Provides Business Update
Globe Newswire•22/10/2026•01:00 ET
0
Key Highlights
- ➤VYVGART product net sales reached $1.7 billion, up 54% year-over-year
- ➤argenx reported third-quarter profit of $506 million, up from $344 million
- ➤VYVGART pediatric gMG applications received FDA priority review, with February 2027 action date
- ➤Empasiprubart Phase 3 MMN topline results expected in December 2026
- ➤2026 combined R&D and SG&A expense forecast set at approximately $4 billion
Expert Statements
Karen Massey, Chief Executive Officer of argenx
“The story of argenx is one of continued innovation, growth and impact.”
Karen Massey, Chief Executive Officer of argenx
“VYVGART is the foundation of our business and continues to deliver strong performance across gMG and CIDP, with significant opportunity still ahead as we reach more patients, expand into new indications, and advance the next wave of FcRn medicines.”
Karen Massey, Chief Executive Officer of argenx
“The positive results from our Phase 3 ALKIVIA study further reinforce the potential of VYVGART beyond neurology, and underscore how much more it can deliver for patients.”
Karen Massey, Chief Executive Officer of argenx
“The upcoming Phase 3 readout for empasiprubart in MMN, the advancement of FB102, and progress across our emerging immunology pipeline are bringing the next chapter of argenx into focus as we build a global immunology innovator positioned for durable growth and value creation well beyond Vision 2030.”
Continued strong VYVGART performance drives $1.7 billion in global product net sales, representing 54% year-over-year growth and 13% quarter-over-quarter growth
sBLA for VYVGART Hytrulo in IMNM on track for submission by year-end; pursuing additional registrational study in DM
Get started
Create a free account to read the full story.